Afatinib is a potent oral agent that selectively and irreversible blocks receptors in the ErbB Family, including EGFR (also called ErbB-1). The expanded access program (EAP) is available to provide early acces to patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR mutation(s): LUX-Lung EAP US; An open label expanded access program of afatinib (BIBW 2992) for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutation(s)
The EAP is set up as a clinical research trial but has less restrictive inclusion and exclusion criteria . Key inclusions criteria are locally advanced or metastatic Non-Small Cell Lung Cancer and the presence of EGFR mutation (For more information see ClinicalTrials.gov).
The EAP is available at our Long Beach Elm Office. For more information call Irene at 562-590-0345.